US · guidance
CMS Pub. 100-18, ch. 6, § 30.4.11
Public Notice of Transition Process
Part D sponsors must make general information about their transition processes available to
beneficiaries in a manner similar to information provided on formularies and benefit design. It is
likely that individuals will base their decision on which prescription drug best meets their needs
on a variety of factors. Having information about a sponsor’s transition process in plan
enrollment materials and Web sites, as well as on the Medicare Prescription Drug Plan Finder,
may reassure beneficiaries that there will be procedures in place to assist them in switching to
therapeutic alternatives or in obtaining a formulary exception where appropriate. It will also
serve to educate advocates and other interested third parties – for example, State Medicaid
agencies – about sponsor transition processes. CMS will make plan transition process
information available via a required link from the Medicare Prescription Drug Plan Finder to
individual sponsor Web sites.
History
(Rev. 18, Issued: 01-15-16, Effective: 01-15-16; Implementation: 01-15-16)
Provenance
- Source
- cms.gov
- Retrieved
- 2026-09-17
- Edition
- iom-2026-09-17
- Content hash
d0bf22b67cd4fb90f55985b7ba841d4bae1c4d73674f6974998161a525c7674a
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.